Literature DB >> 25310035

Prognostic impact of epithelial cell adhesion molecule in ovarian cancer patients.

Maria Lee1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25310035      PMCID： PMC4195308          DOI： 10.3802/jgo.2014.25.4.352

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN： 2005-0380            Impact factor:   4.401


× No keyword cloud information.
  14 in total

1.  Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors.

Authors:  Philip Went; Stephan Dirnhofer; Tiziana Salvisberg; Mahul B Amin; So D Lim; Pierre-André Diener; Holger Moch
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

Review 2.  EpCAM in carcinogenesis: the good, the bad or the ugly.

Authors:  Bernardina T F van der Gun; Lieuwe J Melchers; Marcel H J Ruiters; Lou F M H de Leij; Pamela M J McLaughlin; Marianne G Rots
Journal:  Carcinogenesis       Date:  2010-09-13       Impact factor: 4.944

3.  High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.

Authors:  Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Ronald Simon; Hanspeter Spichtin; Robert Maurer; Urs Metzger; Brida von Castelberg; Rahel Bart; Shanna Stopatschinskaya; Ossi Robert Köchli; Philip Haas; Friedrich Mross; Markus Zuber; Holger Dietrich; Susanne Bischoff; Martina Mirlacher; Guido Sauter; Guenther Gastl
Journal:  Breast Cancer Res Treat       Date:  2004-08       Impact factor: 4.872

4.  Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

Authors:  Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Holger Moch; Patrick A Baeuerle; Elisabeth Mueller-Holzner; Christian Marth; Guenther Gastl; Alain G Zeimet
Journal:  Gynecol Oncol       Date:  2006-05-06       Impact factor: 5.482

5.  A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells.

Authors:  Ralf Gutzmer; Wei Li; Shaheen Sutterwala; Maria P Lemos; J Ignasi Elizalde; Sandra L Urtishak; Edward M Behrens; Patricia M Rivers; Katia Schlienger; Terri M Laufer; Stephen L Eck; Michael S Marks
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

6.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors:  Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

7.  Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.

Authors:  Stefania Bellone; Eric R Siegel; Emiliano Cocco; Marilisa Cargnelutti; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Int J Gynecol Cancer       Date:  2009-07       Impact factor: 3.437

8.  Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival.

Authors:  Meri Varga; Peter Obrist; Stephan Schneeberger; Gilbert Mühlmann; Christina Felgel-Farnholz; Dominic Fong; Mathias Zitt; Thomas Brunhuber; Georg Schäfer; Guenther Gastl; Gilbert Spizzo
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

9.  Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

Authors:  P Went; M Vasei; L Bubendorf; L Terracciano; L Tornillo; U Riede; J Kononen; R Simon; G Sauter; P A Baeuerle
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

Review 10.  EpCAM (CD326) finding its role in cancer.

Authors:  P A Baeuerle; O Gires
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640
View more
  2 in total

1.  NDRG2 Expression Decreases Tumor-Induced Osteoclast Differentiation by Down-regulating ICAM1 in Breast Cancer Cells.

Authors:  Bomi Kim; Sorim Nam; Ji Hyun Lim; Jong-Seok Lim
Journal:  Biomol Ther (Seoul)       Date:  2016-01-01       Impact factor: 4.634

2.  Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer.

Authors:  Rachel Topno; Ibha Singh; Manoj Kumar; Pallavi Agarwal
Journal:  BMC Cancer       Date:  2021-03-04       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.